InnoCare Pharma Limited provided earnings guidance for the year ended 31 December 2022. The net profit attributable to owners of the parent company in 2022 is expected to be RMB 910 million, representing an increase in loss of approximately 1,309.8% as compared with that of the corresponding period of the previous year. The net profit after excluding non-recurring gains or losses attributable to owners of the parent company in 2022 is expected to be RMB 950 million, representing an increase in loss of approximately 1,670.4% as compared with that of the corresponding period of the previous year.